Physician profile
Christopher S Ho
NPI 1972774958
$86,555.95
in general payments reported to CMS, 2019-2025
66 companies · $10K in 2025
The $10K reported for 2025 was more than what 89% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20K · 2020: $8,133 · 2021: $20K · 2022: $13K · 2023: $9,122 · 2024: $5,732 · 2025: $10K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14K · Food and Beverage: $8,730 · Consulting Fee: $1,500 · Travel and Lodging: $819 · Education: $214.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,710.00 |
| Food and Beverage | $8,729.86 |
| Consulting Fee | $1,500.00 |
| Travel and Lodging | $818.82 |
| Education | $213.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Foundation Medicine, INC. | $38,620.89 | 2019-2023 | Foundationone Cdx |
| Astrazeneca Pharmaceuticals LP | $17,678.09 | 2019-2025 | Lynparza, Enhertu, Calquence |
| Amgen INC. | $7,394.68 | 2019-2025 | Otezla, Prolia, Evenity |
| Pfizer INC. | $5,447.92 | 2019-2025 | |
| Emd Serono, INC. | $2,469.01 | 2020-2025 | Bavencio, Tepmetko |
| E.R. Squibb & Sons, L.L.C. | $1,869.78 | 2019-2025 | Opdivo, Eliquis, Opdualag |
| Blueprint Medicines Corporation | $1,380.59 | 2021-2025 | Ayvakit |
| Genentech USA, INC. | $1,076.06 | 2019-2025 | Tecentriq, Venclexta, Polivy |
| Novartis Pharmaceuticals Corporation | $817.28 | 2019-2025 | |
| Incyte Corporation | $804.64 | 2019-2025 | Jakafi |
| Merck Sharp & Dohme LLC | $778.26 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Janssen Biotech, INC. | $610.85 | 2019-2025 | Tecvayli, Darzalex, Rybrevant |
| Genzyme Corporation | $549.84 | 2019-2025 | |
| Astellas Pharma US INC | $537.93 | 2023-2025 | Xospata, Vyloy, Xtandi |
| Lilly USA, LLC | $492.07 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
Show all 66 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $383.99 | 2020-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $364.05 | 2020-2024 | |
| Glaxosmithkline, LLC. | $362.95 | 2020-2025 | Zejula, Jemperli |
| Gilead Sciences, INC. | $337.24 | 2022-2025 | Trodelvy |
| Celgene Corporation | $331.30 | 2021-2025 | Reblozyl, Opdualag, Pomalyst |
| Karyopharm Therapeutics INC. | $312.09 | 2020-2024 | Xpovio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $298.12 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $251.27 | 2020-2025 | Ultomiris |
| Seagen INC. | $237.56 | 2019-2023 | Tukysa, Adcetris |
| Daiichi Sankyo INC. | $214.88 | 2021-2025 | Enhertu |
| Dendreon Pharmaceuticals LLC | $195.40 | 2019-2021 | |
| Exelixis INC. | $177.42 | 2020-2022 | |
| Regeneron Healthcare Solutions, INC. | $165.72 | 2019-2024 | Libtayo |
| Pharmaessentia USA Corporation | $145.38 | 2024-2025 | Besremi |
| Blue Earth Diagnostics | $128.91 | 2021-2023 | |
| Tempus Ai, INC | $126.25 | 2024-2025 | Xt Cdx |
| Sobi, INC | $125.43 | 2024-2025 | |
| Jazz Pharmaceuticals INC. | $123.97 | 2024-2025 | |
| Adc Therapeutics America, INC. | $119.13 | 2021-2024 | |
| Taiho Oncology, INC. | $117.28 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $106.75 | 2022-2024 | Ninlaro, Fruzaqla |
| Abbvie INC. | $104.08 | 2023-2024 | |
| Morphosys, US INC. | $93.95 | 2021-2024 | Monjuvi |
| Tersera Therapeutics LLC | $93.19 | 2021-2022 | |
| Agios Pharmaceuticals, INC. | $90.15 | 2024-2025 | Pyrukynd |
| Aveo Pharmaceuticals, INC. | $87.71 | 2022-2023 | Fotivda |
| Helsinn Therapeutics (U.S.), INC. | $79.10 | 2019-2024 | Akynzeo |
| Octapharma USA, INC. | $71.92 | 2024-2025 | Octagam Immune Globulin (Human) |
| Caris Mpi, INC. | $68.63 | 2025 | Mi Cancer Seek |
| Stemline Therapeutics INC. | $67.97 | 2023 | Orserdu |
| Array Biopharma INC | $57.32 | 2024-2025 | Mektovi, Braftovi, Lorbrena |
| Legend Biotech USA INC. | $51.18 | 2024-2025 | Carvykti |
| Ipsen Biopharmaceuticals, INC | $51.15 | 2019-2024 | Onivyde |
| Deciphera Pharmaceuticals INC. | $47.62 | 2021-2023 | Qinlock |
| Tolmar Pharmaceuticals, INC. | $45.20 | 2021-2022 | |
| Tesaro, INC. | $44.90 | 2019 | |
| Beigene USA, INC. | $43.12 | 2021-2024 | Brukinsa |
| Kite Pharma, INC. | $31.09 | 2022 | |
| Syndax Pharmaceuticals, INC. | $26.60 | 2025 | |
| Global Blood Therapeutics, INC. | $25.68 | 2022 | |
| Azurity Pharmaceuticals, INC. | $25.64 | 2025 | Danziten |
| Mirati Therapeutics, INC. | $23.62 | 2023 | Krazati |
| Sanofi-Aventis U.S. LLC | $23.17 | 2019 | |
| Csl Behring | $23.09 | 2019 | |
| Cti Biopharma Corp. | $22.41 | 2022 | |
| Novocure INC. | $21.62 | 2024 | Optune Lua (Novottf-200t) |
| Rigel Pharmaceuticals, INC. | $20.82 | 2019 | |
| Puma Biotechnology, INC. | $18.79 | 2022 | |
| Secura Bio, INC. | $17.18 | 2021 | |
| Cranial Technologies, INC | $14.37 | 2024 | Doc Band |
| Boston Scientific Corporation | $11.70 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Ho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.